Citadel Advisors’s Cellectis CLLS Stock Holding History
Bought
Maintained
Sold
Other funds holding CLLS
BGI
LFCM
NAMI
Citadel Advisors's CLLS Position: Q1 2026 in Review
Citadel Advisors reduced its Cellectis (CLLS) stake by 54% in Q1 2026, selling an estimated $196K and leaving 44,315 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #11740.
Citadel Advisors first reported a position in CLLS in Q1 2015 and has held it in 40 quarters since. The position peaked at $8.53M in Q4 2019. 32 funds tracked by Wall St. Rank hold CLLS as of Q1 2026.
- Citadel Advisors held 44,315 shares of Cellectis worth $140K as of Q1 2026.
- Citadel Advisors sold 51,112 Cellectis shares in Q1 2026, an estimated $196K.
- Cellectis made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11740 holding.
- Citadel Advisors first reported a position in Cellectis in Q1 2015 and has held it in 40 quarters since.
- Citadel Advisors's Cellectis position peaked at $8.53M in Q4 2019.
- 32 funds tracked by Wall St. Rank held Cellectis as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.